Hepatitis B Testing Market
Hepatitis B Testing Market Projected To Grow With Significant CAGR Over The Forecast Period
Hepatitis B is a liver disease caused by the Hepatitis B virus (HBV). Hepatitis B viral infection can form mild infection which last few weeks and also can cause a chronic infection that may lead to liver disorders and even death. Hepatitis B is one of the global health problem. Hepatitis B can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer. The virus is transmitted through contact with the blood or other body fluids of an infected person.
Increased liver cancer cases, growing aging population, healthcare spending and urbanization are leading to better monitoring and screening procedures. In addition, government initiatives in growing awareness in public, increase in R&D expenditure by companies and growing demand for bio marker tests due to its accuracy expected to boost the hepatitis B virus testing market. However, factors such as lack of awareness in developing countries, stringent regulatory rules, rigid competition and high cost of testing are expected to hamper the hepatitis B virus testing market.
Free sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-b-virus-testing-market/#ulp-4H8Z4LpNMLEuOnnx
The global hepatitis B virus testing market is classified on the basis of following categories-
1. Test type
• Hepatitis B Surface Antigen Test (HBsAg)
• Anti-hepatitis B Surface Antibody Test
• Hepatitis B Core Antigen Test (HBcAb)
• Anti-hepatitis B Core Antibody Test
• HBV DNA Test
• Others
2. Techniques
• PCR
• Radioimmunoassay (RIA)
• Enzyme-linked immunosorbent assay (ELISA)
• Others
3. End-users
Hospitals, diagnostic centers and clinics
Free TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-b-virus-testing-market/#ulp-c654SbFYO64MsOhu
And lastly, on the basis of geographical regions, hepatitis B virus testing market is divided into North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa. North America dominates the hepatitis B testing market owing to the high awareness levels, availability of improved infrastructure, and favorable government initiatives relating to the promotion of hepatitis B therapeutics. Europe is the second largest market for hepatitis B therapeutics driven by rising geriatric population, high rates of chronic infections in Central and Eastern Europe. European Centre for Disease Prevention and Control (ECDC) estimates an overall hepatitis B incidence of 1.49 per 100 000, prevalence of hepatitis B is the highest in Middle East & Africa where adult population is chronically infected. According to World Health Organization (WHO), 2% to 5% of population is affected with hepatitis B virus in Asia Pacific region. And most people die with liver diseases.
Some of the key players hepatitis B virus testing market are Onsite Lab Holding AG (MedMira Inc.) (Switzerland), F. Hoffmann-La Roche (Switzerland), Abbott Laboratories (USA), Siemens AG (Siemens Healthcare GmbH) (Germany), Fisher Bioblock Bolding (Thermo Fisher Scientific) (France), Innovita biological technology Co. Ltd. (China), General Biologicals Corporation (Taiwan), Nantong Diagnos Biotechnology Co. Ltd. (China), Blue Cross Bio-Medical (China) Co. Ltd., BioGenex (U.S.), and Abnova Corporation (U.S.) among others. In 2011, Roche received Premarket Approval from USFDA for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay for use on the Cobas e 601 analyzers, the immunoassay module of the Cobas 6000 (hepatitis B test) analyzer. And in 2010, Abbott received USFDA approval for its RealTime HBV assay, first and only approved test capable of automating HBV viral load testing.
Ask Analyst for Full Information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-b-virus-testing-market/#ulp-14mlyhjMGhVjZqa3
Currently, more than 13 immunoassays are available to diagnose hepatitis B virus at an early stage. They can also be used to distinguish acute and chronic hepatitis B infections. Many governments in the European countries and the US made it mandatory for the people to go through the screening and proper monitoring since hepatitis B takes the time to develop and is not easily detected. There are some curative therapies available but they are not very efficient. It is expected that many innovative therapies which have shown positive results in trials will occupy the market in the coming years. Many companies have products related to hepatitis B in their pipeline. Vendors are developing devices and systems that help integrate laboratory applications. For instance, in 2010 the COBAS 6000 modular platform by Roche Diagnostics offers optimum efficiency and consolidation in medium- and high-volume laboratories.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-b-virus-testing-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com